Therefore, YAP/TAZ activation probably contributes to the malignant behavior of mesenchymal NSCLC cells, and YAP/TAZ inhibition by statins might be a useful anticancer strategy. This evidence concerns the gene YAP1 and non-small cell lung carcinoma.